dr om manchanda on dr lal pathlabs' weak q3 earnings & outlook | bazaar corporate radar | cnbc-tv18
Published 1 year ago • 4.3K plays • Length 8:50Download video MP4
Download video MP3
Similar videos
-
8:33
dr lal path labs' om manchanda speaks on q4 performance & fy24 margin outlook | cnbc-tv18
-
9:12
aspiration is to grow in double digit with margin at 26% in fy25: dr lal pathlabs | cnbc tv18
-
16:07
dr lal path labs' om manchanda exclusive on the changing landscape of diagnostics | the medicine box
-
9:16
price increase is one of the reasons for the margin expansion: dr lal pathlabs | cnbc tv18
-
9:05
how is dr. lal pathlabs trading today?| bazaar corporate radar
-
14:03
dr lal pathlabs ceo explains business model
-
1:36:09
discussion with nandan nilekani & saurabh mukherjea - "how digital public goods are changing india"
-
2:44
dr. arvind lal and dr. om manchanda, chairman and ceo lal pathlabs : eoy india 2015 award finalists
-
7:21
dr lal path labs' om manchanda speaks on rising competition in diagnostics | bazaar open exchange
-
13:37
dr om manchanda, md, dr lal pathlabs on strong q4 results & growth plans for fy25
-
0:50
bull vs bear | contrasting brokerage views on dr lal path labs post q3 earnings | cnbc tv18
-
10:12
diagnostics will continue to remain the mainstay within healthcare: dr lal path labs | cnbc tv18
-
27:16
know all about dr lal path labs, srl diagnostics' ipo & apollo hospitals | the medicine box
-
22:31
dr lal path labs, fortis healthcare & apollo; deep dive into key players of diagnostic business
-
7:40
dr lal pathlabs' bharath uppiliappan speaks on the firm's q2fy23 results | bazaar morning call
-
4:11
'demand & supply landscape of diagnostic industry changing', says om manchanda | halftime report
-
6:20
new entrants have led to heavy discounting in the industry: dr lal pathlabs' om manchanda
-
6:39
dr lal pathlabs' arvind lal speaks on delhi govt's free medical tests drive & the firm's biz outlook
-
11:35
dr pathlabs md om manchanda speaks on india's covid testing picture | coronavirus pandemic
-
1:24
goldman sachs downgrades dr lal pathlabs & metropolis healthcare to sell, slashes target price
-
4:42
dr lal pathlabs: q1, margins, expansion plans & capex | dr. om manchanda explains | business news
-
5:46
divi's laboratories q3 profit after tax drops 66% yoy to ₹307 crore: vishal manchanda exclusive